Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.
Rose McGowan
Advertisement
Articles by Rose McGowan
Advertisement
Latest Updated Articles
Dupilumab Reduces COPD Exacerbations for Patient with T2 Inflammation in Landmark Phase 3 TrialPublished: May 22nd 2023 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease
2
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
3
Menopause Education Lags in Residency Training Across Primary Care Specialties
4
Menopause: A Constellation of Syndromes Across 13 Body Systems
5
